Federal regulators have granted clearance to a novel diagnostic tool designed to assist healthcare professionals in identifying autism spectrum disorder among children, marking another step forward in the integration of artificial intelligence and biometrics into pediatric care.
The Food and Drug Administration cleared the tool, known as Neurora, this month to help inform clinical decisions when evaluating children ranging from 18 months to 12 years old. Developed by Argus Cognitive, Inc., the technology relies on more than 100 distinct biometrics to assess whether a child exhibits developmental indicators consistent with autism.
The approval arrives as families across the country continue to navigate substantial hurdles in accessing timely developmental evaluations. According to recent estimates from the Centers for Disease Control and Prevention, autism affects approximately 1 in 31 children. Despite high prevalence rates, many families face extensive waiting lists to secure professional assessments, with the federal agency noting that the median age of diagnosis currently stands at just under 4 years old.
The newly cleared system is designed to streamline and support the evaluation workflow already established by pediatricians and specialists. Under the process outlined by Argus Cognitive, clinicians can upload video and audio recordings captured during standard behavioral assessments into the secure Neurora portal. Once uploaded, the automated tool meticulously measures a wide array of behavioral markers, including facial expressions, vocal patterns, and eye-gaze dynamics. By analyzing these variables, the software evaluates how an individual child’s behavioral profile compares against extensive datasets representing children both with and without autism.
Company executives emphasize that the technology is intended strictly as a supporting instrument rather than a standalone diagnostic mechanism. The resulting data points are meant to be considered in conjunction with other clinical findings and professional judgment.
Dr. Attila Meretei, CEO and co-founder of Argus Cognitive, underscored the practical philosophy guiding the tool’s integration into clinical settings. "We built Neurora to support clinicians evaluating children for autism," Meretei said. "Neurora works inside the assessment clinicians already use, without protocol changes or proprietary hardware, and is fully automated. Our goal is to reinforce every diagnosis with robust, quantitative evidence."
The journey from concept to regulatory clearance involved rigorous scientific validation and external support. Argus Cognitive reported that the development of Neurora was supported in part by a competitive research grant for entrepreneurs awarded by the National Institutes of Health. Furthermore, the clinical utility and reliability of the device were bolstered by a peer-reviewed study published earlier this year in the journal Frontiers in Psychiatry. That research demonstrated that the biometric tool successfully distinguished between children with and without autism in nearly 78 percent of evaluated cases, providing the foundational empirical data necessary for federal regulatory review.
Neurora joins a small but growing ecosystem of authorized digital and hardware-based medical devices now available to pediatric diagnosticians seeking objective, quantitative data to aid complex behavioral evaluations. In recent years, the FDA has cleared a few other specialized diagnostic aids aimed at earlier and more precise identification.
Among them is the EarliPoint Evaluation for ASD, which utilizes specialized eye-tracking technology to analyze visual attention and social engagement behaviors in young children. Additionally, the agency previously cleared Canvas Dx, an algorithm-driven software platform that analyzes background information submitted by parents and healthcare providers alongside video recordings of the child to help guide clinical decision-making regarding potential diagnoses.
As health systems grapple with surging demand for developmental evaluations and persistent shortages of pediatric specialists, the introduction of automated biometric tools like Neurora reflects a broader shift toward integrating data-driven technologies into everyday pediatric practice. By providing clinicians with quantitative reinforcement during standard assessments, developers and researchers hope to reduce diagnostic bottlenecks, minimize subjectivity in early childhood evaluations, and ultimately help families secure necessary therapeutic interventions much earlier in a child’s development.
